Sanara MedTech stock price rises over 3% despite Q4 earnings missing expectations

LootboxPhobia · 2026-03-24T15:45:01+00:00

Sanara MedTech Inc. reported fourth-quarter results that missed expectations, with a loss per share of $0.19 and revenue of $27.5 million. Despite this, the stock rose 3.44% in after-hours trading. The company reiterated its fiscal 2026 revenue guidance of $116 million to $121 million, representing expected growth of 13% to 17%. The president stated that net revenue is expected to exceed $100 million in 2025, representing year-over-year growth of 19%.

LootboxPhobia

2026-03-24 15:45:01

Abstract generation in progress

Fort Worth, Texas — On Tuesday, Sanara MedTech Inc. (NASDAQ: SMTI) reported fourth-quarter results that missed analyst expectations and reaffirmed its full-year guidance for fiscal 2026. The company’s stock rose 3.44% in after-hours trading.

The medical technology company posted a fourth-quarter loss of $0.19 per share, better than the analyst consensus of $0.33, a difference of $0.52. Revenue reached $27.5 million, slightly below the market expectation of $27.78 million but up 5% from $26.3 million in the same period last year.

Excluding approximately $1.8 million in unconventional sales from BIASURGE in Q4 2024 caused by supply chain disruptions from Hurricane Helen, revenue grew 13% year-over-year.

For the full fiscal year 2025, Sanara reported revenue of $103.1 million, up 19% from $86.7 million in 2024.

The company reaffirmed its revenue guidance for 2026, projecting $116 million to $121 million, representing a 13% to 17% increase. The midpoint of $118.5 million indicates ongoing expansion in the surgical market.

President and CEO Seth Yon stated, “We are pleased to achieve strong sales performance in 2025, with our first full-year net revenue exceeding $100 million, a 19% increase year-over-year.”

Gross margin for Q4 expanded from 91% in the same period last year to 93%, driven by increased sales of soft tissue repair products and lower manufacturing costs for CellerateRX Surgical. However, operating expenses rose 13% year-over-year to $24.6 million, including $1.8 million in non-cash asset impairment related to intellectual property write-downs.

This article was translated with the assistance of artificial intelligence. For more information, see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.